Clinical News

Capmatinib showed anti-tumor activity in MET-amplified advanced NSCLC


MET gene is one of the important oncogenes in advanced non-small cell lung cancer (NSCLC).  The Japanese Ministry of Health, Labour and Welfare (MHLW) and the U.S. Food and Drug Administration (FDA) have approved tepotinib and capmatinib respectively for the treatment of patients with MET exon 14 skipping advanced NSCLC. MET amplification is the other genetic alteration of the MET gene. About 1-6% of NSCLC has MET amplification. In a phase II study (GEOMETRY mono-1), treatment-naïve and pretreated patients with MET-amplified advanced NSCLC received capmatinib for treatment. In the treatment naïve cohort, the response rate was 40%, the median duration of response was 7.54 months; In the pretreated cohort, the response rate was 29%, the median duration of response was 8.31 months. The results showed the anti-tumor activity of capmatinib in MET-amplified advanced NSCLC.

J Clin Oncol 38: 2020 (suppl; abstr 9509)